Fruquintinib

Phase 1Completed

1 views this week 0 watching💤 Quiet

Interest: 23/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Tumor

Conditions

Tumor

Trial Timeline

Jan 1, 2011 → Oct 1, 2012

NCT ID

NCT01645215

About Fruquintinib

Fruquintinib is a phase 1 stage product being developed by HUTCHMED for Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT01645215. Target conditions include Tumor.

What happened to similar drugs?

20 of 20 similar drugs in Tumor were approved

Approved (20) Terminated (3) Active (0)

✅PexidartinibDaiichi SankyoApproved

✅KRN23Kyowa KirinApproved

✅DurvalumabAstraZenecaApproved

✅aprepitant + Dexamethasone and Ondansetron during CE-treatmentMerckApproved

✅Everolimus (RAD001)NovartisApproved

✅Chromogranin ANovartisApproved

✅Pasireotide + DiazoxideNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05216354	Phase 1	Completed	Mar 11, 2022	Jun 26, 2023	Renal Impairment
NCT05216367	Phase 1	Completed	Mar 11, 2022	Oct 25, 2022	Hepatic Impairment
NCT03684967	Phase 2	Withdrawn	May 8, 2018	Sep 6, 2019	Lung Cancer
NCT02689752	Phase 1	Completed	Jul 1, 2016	Sep 1, 2016	Healthy
NCT01975077	Phase 1/2	Completed	Dec 1, 2012	Oct 1, 2014	Colorectal Cancer
NCT01955304	Phase 1	Completed	Jun 1, 2012	Dec 1, 2012	Food Effect of Fruquintinib in Health Subjects
NCT01645215	Phase 1	Completed	Jan 1, 2011	Oct 1, 2012	Tumor

Competing Products

20 competing products in Tumor

See all competitors

Product	Company	Stage	Hype Score
ALG.APV-527	Alligator Bioscience AB	Phase 1/2	18
ATOR-1017	Alligator Bioscience AB	Phase 1	19
ATOR-1015	Alligator Bioscience AB	Phase 1	19
mRNA-4359	Moderna	Phase 2	0
mRNA-2752 + Durvalumab	AstraZeneca	Phase 1	29
mRNA-4106	Moderna	Phase 1	0
mRNA-4157 + Pembrolizumab + SoC Treatment	Merck	Phase 1	33
mRNA-2416	Moderna	Phase 2	0
E7050	Eisai	Phase 1	29
AFM24 + Atezolizumab 840 MG in 14 ML Injection	Affimed	Phase 1/2	14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)	Syros Pharmaceuticals	Phase 1	11
BBP-398 + sotorasib	BridgeBio Pharma	Phase 1	18
BBP-398 (Formerly known as IACS-15509)	BridgeBio Pharma	Phase 1	18
Cixutumumab	Eli Lilly	Phase 1	29
SON-1010	Sonnet BioTherapeutics	Phase 1	27
SON-1010	Sonnet BioTherapeutics	Phase 1/2	18
[203Pb]VMT-α-NET + [212Pb]VMT-α-NET	Perspective Therapeutics	Phase 1/2	33
[203Pb]VMT-α-NET	Perspective Therapeutics	Phase 1	27
[212Pb] VMT-α-NET	Perspective Therapeutics	Phase 1	27
NL-201 + Pembrolizumab Injection [Keytruda]	Neurogene	Phase 1	19